Carl Cook

470 total citations
12 papers, 137 citations indexed

About

Carl Cook is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Carl Cook has authored 12 papers receiving a total of 137 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Carl Cook's work include Lung Cancer Treatments and Mutations (6 papers), Advanced Breast Cancer Therapies (3 papers) and Cancer Genomics and Diagnostics (3 papers). Carl Cook is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Advanced Breast Cancer Therapies (3 papers) and Cancer Genomics and Diagnostics (3 papers). Carl Cook collaborates with scholars based in United States, United Kingdom and Spain. Carl Cook's co-authors include Ganesh Mugundu, Martin Scott, David S. Hong, Ulrich Keilholz, Minal Mehta, Patricia McCoon, Ezra E.W. Cohen, Pat Mitchell, Erika Hamilton and Paul D. Lyne and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Carl Cook

11 papers receiving 136 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carl Cook United States	8	93	59	41	24	12	12	137
Juergen Krauss Germany	7	116 1.2×	53 0.9×	47 1.1×	17 0.7×	13 1.1×	14	167
Hongqian Wu United States	4	93 1.0×	22 0.4×	28 0.7×	29 1.2×	3 0.3×	6	121
Nicholas Venturini United States	5	87 0.9×	42 0.7×	53 1.3×	78 3.3×	2 0.2×	9	164
Jiahan Cheng China	9	37 0.4×	55 0.9×	62 1.5×	31 1.3×	3 0.3×	15	155
María José Echarri Spain	5	101 1.1×	42 0.7×	71 1.7×	12 0.5×	19 1.6×	7	146
Jennifer Friedmann Canada	6	108 1.2×	20 0.3×	58 1.4×	40 1.7×	4 0.3×	16	157
Colleen Maher United States	5	64 0.7×	11 0.2×	22 0.5×	24 1.0×	9 0.8×	12	80
Leonardo Forero United States	4	66 0.7×	47 0.8×	39 1.0×	15 0.6×		7	113
Yujia Chi China	11	110 1.2×	41 0.7×	125 3.0×	21 0.9×	3 0.3×	20	209
Mohammad Atiq United States	6	88 0.9×	54 0.9×	64 1.6×	49 2.0×		21	155

Countries citing papers authored by Carl Cook

Since Specialization

Citations

This map shows the geographic impact of Carl Cook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl Cook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl Cook more than expected).

Fields of papers citing papers by Carl Cook

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carl Cook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl Cook. The network helps show where Carl Cook may publish in the future.

Co-authorship network of co-authors of Carl Cook

This figure shows the co-authorship network connecting the top 25 collaborators of Carl Cook. A scholar is included among the top collaborators of Carl Cook based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carl Cook. Carl Cook is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Schram, Alison M., Jordi Rodón, Manish R. Patel, et al.. (2021). Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies.. Journal of Clinical Oncology. 39(15_suppl). 3086–3086. 16 indexed citations

Lucas, Matthew C., Melinda S. Merchant, Matthew O’Connor, et al.. (2021). Abstract P02-04: BDTX-1535, a CNS penetrant MasterKey inhibitor of common, uncommon and resistant EGFR mutations, demonstrates in vivo efficacy and has potential to treat osimertinib-resistant NSCLC with or without brain metastases. Molecular Cancer Therapeutics. 20(12_Supplement). P02–4.

Hamilton, Erika, Manish R. Patel, Jordi Rodón, et al.. (2020). Masterkey-01: Phase I/II, open-label multicenter study to assess safety, tolerability, pharmacokinetics, and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies.. Journal of Clinical Oncology. 38(15_suppl). TPS3665–TPS3665. 6 indexed citations

Xu, Hongmei, Ganesh Mugundu, Martin Scott, et al.. (2019). Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch. Journal of Pharmacokinetics and Pharmacodynamics. 46(1). 65–74. 11 indexed citations

Vita, Serena De, Janet L. Karlix, Carl Cook, et al.. (2019). First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data.. Journal of Clinical Oncology. 37(15_suppl). 3085–3085. 17 indexed citations

Cohen, Ezra E.W., Kevin J. Harrington, David S. Hong, et al.. (2018). A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results. Annals of Oncology. 29. viii372–viii372. 30 indexed citations

Cohen, Ezra E.W., David S. Hong, William N. William, et al.. (2017). Phase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN). Annals of Oncology. 28. v403–v403. 19 indexed citations

Hong, David S., Gerald S. Falchook, Carl Cook, et al.. (2016). A phase 1b study (SCORES) assessing safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of durvalumab combined with AZD9150 or AZD5069 in patients with advanced solid malignancies and SCCHN. Annals of Oncology. 27. vi360–vi360. 7 indexed citations

Bauer, Todd M., Suzanne F. Jones, Carol Greenlees, et al.. (2016). Abstract CT013: A phase Ib, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of AZD1775 monotherapy in patients with advanced solid tumors: initial findings. Cancer Research. 76(14_Supplement). CT013–CT013. 7 indexed citations

10.

Bauer, Todd M., Suzanne F. Jones, Carol Greenlees, et al.. (2016). A Phase Ib, Open-Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of AZD1775 Monotherapy in Patients with Advanced Solid Tumors: Expansion Cohorts.. Journal of Clinical Oncology. 34(15_suppl). TPS2608–TPS2608. 8 indexed citations

11.

Hamilton, Erika, Gerald S. Falchook, Suzanne F. Jones, et al.. (2016). A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors.. Journal of Clinical Oncology. 34(15_suppl). 5562–5562. 10 indexed citations

12.

Cook, Carl, et al.. (2000). An Artificial Neural Network for the Electrocardiographic Diagnosis of Left Ventricular Hypertrophy. Critical Reviews in Biomedical Engineering. 28(3-4). 435–438. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact